More on ABT
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $104.88 |
|
|||
| Open | $102.81 | ||||
| 52 Wk High | $46.38 | ||||
| 52 Wk Low | $36.00 | ||||
| Day High | $104.28 | ||||
| Day Low | $101.91 | ||||
| P/E | 68.73 | ||||
| EPS | $1.50 | ||||
| Volume | 6,491,103 | ||||
- Argus Downgrades Abbott Labs (ABT) to Hold
- Abbott launches next-generation Oncodetect cancer MRD blood test
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- StoneX Reiterates Buy Rating on Abbott Labs (ABT)
- Abbott WGS cancer test shows 30-point sensitivity gain in study
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Abbott Labs (ABT) PT Raised to $120 at Bernstein SocGen Group
- Abbott Labs (ABT) PT Lowered to $118 at TD Cowen
- Abbott Labs (ABT) PT Lowered to $118 at JPMorgan
- Mizuho on Abbott Labs (ABT): 'Nutrition Spin Well-Telegraphed as Attention Shifts to Libre & C+'
Entities mentioned with ABT
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
